Select a Region
North America

Resources Library

EVERSANA’s deep bench of oncology experts leverage their extensive industry experience to inform strategies and deliver services that pave the way to commercial success. In an effort to share expert knowledge and help manufacturers understand the complexities of commercialization for new oncology therapies, EVERSANA developed a robust library of resources.

Watch recordings from industry-leading conferences, download white papers and review recent media publications.

  • Engaging Oncology Patients and Providers in the Age of COVID and Beyond 詳細情報
  • A PARTNERSHIP Q&A WITH EVERSANA AND SHORLA PHARMA 詳細情報
  • NEXT GEN COMMERCIALIZATION MODEL FOR ONCOLOGY 詳細情報
  • ADDRESSING UNMET MEDICAL NEEDS THROUGH BOLD INNOVATION 詳細情報
  • DRIVING COMMERCIAL EXCELLENCE FOR CAR-T 詳細情報
  • Commercialization Strategies in Oncology — The Right Partner Can Reduce Risk and Boost Rewards 詳細情報
  • CASE STUDY: LAUNCHING A NEW THERAPY FOR BREAST CANCER 詳細情報
  • Case Study: Patient Affordability Programs 詳細情報
  • Case Study: High-Tech Medical Information Services 詳細情報
  • Pivot Pros: How EVERSANA Course Corrected When the Market Changed 詳細情報
  • The Expanding Oncology Market Prompts Reevaluation of Field Team Training Procedures and Skill Set to Impact Frontline Success 詳細情報

Featured Content

Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem

Posted on 1月 26, 2022 1/26/22

As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500 active cell and gene therapy agents in clinical development, with a great momentum building for immuno-oncology treatments. The Oncology Ecosystem Is Changing, and the Cost for Commercialization Is Steep. There is no question about the incredible clinical impact these long-awaited therapies can have on patients and the industry, but launching in the oncology space is not the same as it was 20 years ago for two reasons: Commercialization stakes are high. The average cost […]

Read More

Next Gen Commercialization: Accelerating Patient Access to Life-Changing Therapies

Posted on 6月 29, 2021 6/29/21

Fifty years ago, only half of the patients diagnosed with cancer in the United States would have been alive five years later. By 2009, patient survival climbed to 70%. The problem is, in all our years working in the pharmaceutical industry and oncology, commercialization has not evolved with science. Manufacturers preparing for launch probably only see three options: sell their product to a big box pharmaceutical company, license or co-promote their product to a company with an established infrastructure, or launch internally with their own team. However, today’s unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach with less risk and more value. […]

Read More

NAVLIN Insights delivers the most innovative market research solutions for oncology manufacturers, from pipeline to loss of exclusivity. Our proprietary insights, which are derived from an unrivaled expert panel network, are combined with an advanced set of methods, frameworks and novel solutions to provide competitive intelligence, insights and strategic recommendations to support the best possible access for your therapy.

  • Market Access

    Monitor key trends in commercial and government markets to understand how payers are managing access to oncolytics relative to other therapeutic areas. 

  • Brand Access

    Assess the current and future access environment within a specific cancer type, supporting brand strategies for in-line brands and pipeline assets.

  • Account Access

    Benchmark company performance against competitors of competencies and attributes that promote stronger relationships with cancer centers and oncology group practices.

  • Account Access

    Provide insights on enrollment trends and business strategies of leading cancer centers to support development of effective business and account plans.

  • Patient Access

    Benchmark oncology patient services programs on levels of user importance/value, use, and satisfaction to identify operating gaps and highlight industry best practices, allowing companies to improve patient access to therapy. 

  • Custom Access

    Tap into our panel of payer and leading oncology group executives, as well as practicing oncologists to answer your specific business questions.

Featured Content

Payer Oncology Access Management in 2022

Posted on 11月 3, 2022 11/3/22

Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite to manage access for both oral and office-administered oncology agents, payers struggle with which tactics to implement without sacrificing patient outcomes. ​ ​Pharmaceutical companies should expect to see changes in payer management for oncology over the next 2-3 years. ​ In a recent article, the NAVLIN Insights team outlines payer access management in oncology today and takes a closer look at how access will evolve in the coming years, including the impact of the Inflation Reduction Act and which brands may […]

Read More

Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward

Posted on 3月 13, 2023 3/13/23

Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented pressure to accelerate their speed to market to make a positive clinical impact on patients and the industry. To add an additional layer of complexity, manufacturers may opt to enter their product into a confirmatory trial, which allows the FDA to fast-track drug approvals in disease states where patients have little to no quality treatment options.   Accelerated pathways pose two key challenges:  The FDA is becoming more stringent, leading to an increased likelihood of […]

Read More

Disease awareness is an essential component to successful commercialization, and our award-winning agency, EVERSANA INTOUCH, has mastered the communication complexity of oncology. Learn why they are the trusted partner for oncology manufacturers.

  • Case Study: It’s Time to #OvaryAct

    Awareness about ovarian cancer was lacking. We changed that in a big way.

    詳細情報
  • #OvaryAct GIFS Making a Difference in Patients' Lives

    Real, personal stories make connections to empower patients and caregivers.

    詳細情報
  • #OvaryAct: When the Magic Happens

    Capturing brilliance, sense of hope, energy and strength from a community.

    詳細情報
  • Telehealth's Vital Role in Oncology

    Telehealth can’t be underestimated as a new model to improve patient care.

    詳細情報
  • #EraseTheLine of Care Inequality

    Launching the world's first digital platform designed for Black women by Black women.

    詳細情報
  • #ERASETHELINE Short-Listed for Prestigious D&AD Award
    #ERASETHELINE Short-Listed for Prestigious D&AD Award

    Removing barriers to quality care with a smart and compelling campaign.

    詳細情報
  • #ERASETHELINE MM+M Awards Best in Show 2022 Titanium Recipient

    The line that slashes through the equal sign is the ugliest blemish on all healthcare, symbolizing the many racial and gender disparities that impact African American women.

    詳細情報

Latest News

EVERSANA and Integra Connect Form Strategic Partnership to Advance Next Generation Oncology Commercialization Services Propelled by Real-World Evidence & Technology Platforms

Read Now

Latest News

Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

Read Now

Meet EVERSANA’s Experts in Oncology and Hematology

Discover Now

お問い合わせ

Schedule a meeting today!